(ILMN) Illumina - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US4523271090
Stock:
Total Rating 66
Risk 84
Buy Signal -0.17
| Risk 5d forecast | |
|---|---|
| Volatility | 42.4% |
| Relative Tail Risk | -6.13% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.65 |
| Alpha | 8.60 |
| Character TTM | |
|---|---|
| Beta | 1.275 |
| Beta Downside | 0.718 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.94% |
| CAGR/Max DD | -0.21 |
EPS (Earnings per Share)
Revenue
Description: ILMN Illumina
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 850.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 2.88 > 1.0 |
| NWC/Revenue: 39.24% < 20% (prev 27.42%; Δ 11.82% < -1%) |
| CFO/TA 0.16 > 3% & CFO 1.08b > Net Income 850.0m |
| Net Debt (1.14b) to EBITDA (1.46b): 0.78 < 3 |
| Current Ratio: 2.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (154.0m) vs 12m ago -3.75% < -2% |
| Gross Margin: 66.49% > 18% (prev 0.65%; Δ 6584 % > 0.5%) |
| Asset Turnover: 67.07% > 50% (prev 69.36%; Δ -2.29% > 0%) |
| Interest Coverage Ratio: 9.41 > 6 (EBITDA TTM 1.46b / Interest Expense TTM 126.0m) |
Altman Z'' 2.61
| A: 0.26 (Total Current Assets 3.29b - Total Current Liabilities 1.58b) / Total Assets 6.64b |
| B: -0.06 (Retained Earnings -392.0m / Total Assets 6.64b) |
| C: 0.18 (EBIT TTM 1.19b / Avg Total Assets 6.47b) |
| D: -0.10 (Book Value of Equity -400.0m / Total Liabilities 3.92b) |
| Altman-Z'' Score: 2.61 = A |
Beneish M -3.02
| DSRI: 1.15 (Receivables 854.0m/751.0m, Revenue 4.34b/4.37b) |
| GMI: 0.98 (GM 66.49% / 65.44%) |
| AQI: 0.91 (AQ_t 0.34 / AQ_t-1 0.37) |
| SGI: 0.99 (Revenue 4.34b / 4.37b) |
| TATA: -0.03 (NI 850.0m - CFO 1.08b) / TA 6.64b) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of ILMN shares?
As of February 26, 2026, the stock is trading at USD 121.87 with a total of 1,571,290 shares traded.
Over the past week, the price has changed by +1.48%, over one month by -20.35%, over three months by -5.99% and over the past year by +27.27%.
Over the past week, the price has changed by +1.48%, over one month by -20.35%, over three months by -5.99% and over the past year by +27.27%.
Is ILMN a buy, sell or hold?
Illumina has received a consensus analysts rating of 3.68.
Therefor, it is recommend to hold ILMN.
- StrongBuy: 7
- Buy: 5
- Hold: 11
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the ILMN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 135.8 | 11.5% |
| Analysts Target Price | 135.8 | 11.5% |
ILMN Fundamental Data Overview February 21, 2026
P/E Trailing = 22.0183
P/E Forward = 22.6244
P/S = 4.2247
P/B = 6.559
P/EG = 0.622
Revenue TTM = 4.34b USD
EBIT TTM = 1.19b USD
EBITDA TTM = 1.46b USD
Long Term Debt = 1.49b USD (from longTermDebt, last quarter)
Short Term Debt = 577.0m USD (from shortTermDebt, last quarter)
Debt = 2.55b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.14b USD (from netDebt column, last quarter)
Enterprise Value = 19.48b USD (18.35b + Debt 2.55b - CCE 1.42b)
Interest Coverage Ratio = 9.41 (Ebit TTM 1.19b / Interest Expense TTM 126.0m)
EV/FCF = 20.75x (Enterprise Value 19.48b / FCF TTM 939.0m)
FCF Yield = 4.82% (FCF TTM 939.0m / Enterprise Value 19.48b)
FCF Margin = 21.63% (FCF TTM 939.0m / Revenue TTM 4.34b)
Net Margin = 19.58% (Net Income TTM 850.0m / Revenue TTM 4.34b)
Gross Margin = 66.49% ((Revenue TTM 4.34b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Gross Margin QoQ = 67.04% (prev 67.59%)
Tobins Q-Ratio = 2.93 (Enterprise Value 19.48b / Total Assets 6.64b)
Interest Expense / Debt = 1.02% (Interest Expense 26.0m / Debt 2.55b)
Taxrate = 11.64% (44.0m / 378.0m)
NOPAT = 1.05b (EBIT 1.19b * (1 - 11.64%))
Current Ratio = 2.08 (Total Current Assets 3.29b / Total Current Liabilities 1.58b)
Debt / Equity = 0.94 (Debt 2.55b / totalStockholderEquity, last quarter 2.72b)
Debt / EBITDA = 0.78 (Net Debt 1.14b / EBITDA 1.46b)
Debt / FCF = 1.21 (Net Debt 1.14b / FCF TTM 939.0m)
Total Stockholder Equity = 2.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.13% (Net Income 850.0m / Total Assets 6.64b)
RoE = 34.94% (Net Income TTM 850.0m / Total Stockholder Equity 2.43b)
RoCE = 30.24% (EBIT 1.19b / Capital Employed (Equity 2.43b + L.T.Debt 1.49b))
RoIC = 23.69% (NOPAT 1.05b / Invested Capital 4.42b)
WACC = 9.42% (E(18.35b)/V(20.90b) * Re(10.61%) + D(2.55b)/V(20.90b) * Rd(1.02%) * (1-Tc(0.12)))
Discount Rate = 10.61% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.58%
[DCF] Terminal Value 76.78% ; FCFF base≈847.0m ; Y1≈1.04b ; Y5≈1.78b
[DCF] Fair Price = 145.0 (EV 23.30b - Net Debt 1.14b = Equity 22.17b / Shares 152.9m; r=9.42% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 48.58 | EPS CAGR: 6.39% | SUE: 0.60 | # QB: 0
Revenue Correlation: -50.43 | Revenue CAGR: -1.42% | SUE: 3.20 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.06 | Chg7d=-0.079 | Chg30d=-0.055 | Revisions Net=-4 | Analysts=16
EPS current Year (2026-12-31): EPS=5.13 | Chg7d=+0.056 | Chg30d=+0.071 | Revisions Net=+8 | Growth EPS=+6.1% | Growth Revenue=+4.4%
EPS next Year (2027-12-31): EPS=5.83 | Chg7d=+0.024 | Chg30d=+0.041 | Revisions Net=+6 | Growth EPS=+13.5% | Growth Revenue=+5.4%
[Analyst] Revisions Ratio: -0.50 (2 Up / 6 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.1% (Discount Rate 10.6% - Earnings Yield 4.5%)
[Growth] Growth Spread = -3.0% (Analyst 3.1% - Implied 6.1%)
P/E Forward = 22.6244
P/S = 4.2247
P/B = 6.559
P/EG = 0.622
Revenue TTM = 4.34b USD
EBIT TTM = 1.19b USD
EBITDA TTM = 1.46b USD
Long Term Debt = 1.49b USD (from longTermDebt, last quarter)
Short Term Debt = 577.0m USD (from shortTermDebt, last quarter)
Debt = 2.55b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.14b USD (from netDebt column, last quarter)
Enterprise Value = 19.48b USD (18.35b + Debt 2.55b - CCE 1.42b)
Interest Coverage Ratio = 9.41 (Ebit TTM 1.19b / Interest Expense TTM 126.0m)
EV/FCF = 20.75x (Enterprise Value 19.48b / FCF TTM 939.0m)
FCF Yield = 4.82% (FCF TTM 939.0m / Enterprise Value 19.48b)
FCF Margin = 21.63% (FCF TTM 939.0m / Revenue TTM 4.34b)
Net Margin = 19.58% (Net Income TTM 850.0m / Revenue TTM 4.34b)
Gross Margin = 66.49% ((Revenue TTM 4.34b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Gross Margin QoQ = 67.04% (prev 67.59%)
Tobins Q-Ratio = 2.93 (Enterprise Value 19.48b / Total Assets 6.64b)
Interest Expense / Debt = 1.02% (Interest Expense 26.0m / Debt 2.55b)
Taxrate = 11.64% (44.0m / 378.0m)
NOPAT = 1.05b (EBIT 1.19b * (1 - 11.64%))
Current Ratio = 2.08 (Total Current Assets 3.29b / Total Current Liabilities 1.58b)
Debt / Equity = 0.94 (Debt 2.55b / totalStockholderEquity, last quarter 2.72b)
Debt / EBITDA = 0.78 (Net Debt 1.14b / EBITDA 1.46b)
Debt / FCF = 1.21 (Net Debt 1.14b / FCF TTM 939.0m)
Total Stockholder Equity = 2.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.13% (Net Income 850.0m / Total Assets 6.64b)
RoE = 34.94% (Net Income TTM 850.0m / Total Stockholder Equity 2.43b)
RoCE = 30.24% (EBIT 1.19b / Capital Employed (Equity 2.43b + L.T.Debt 1.49b))
RoIC = 23.69% (NOPAT 1.05b / Invested Capital 4.42b)
WACC = 9.42% (E(18.35b)/V(20.90b) * Re(10.61%) + D(2.55b)/V(20.90b) * Rd(1.02%) * (1-Tc(0.12)))
Discount Rate = 10.61% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.58%
[DCF] Terminal Value 76.78% ; FCFF base≈847.0m ; Y1≈1.04b ; Y5≈1.78b
[DCF] Fair Price = 145.0 (EV 23.30b - Net Debt 1.14b = Equity 22.17b / Shares 152.9m; r=9.42% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 48.58 | EPS CAGR: 6.39% | SUE: 0.60 | # QB: 0
Revenue Correlation: -50.43 | Revenue CAGR: -1.42% | SUE: 3.20 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.06 | Chg7d=-0.079 | Chg30d=-0.055 | Revisions Net=-4 | Analysts=16
EPS current Year (2026-12-31): EPS=5.13 | Chg7d=+0.056 | Chg30d=+0.071 | Revisions Net=+8 | Growth EPS=+6.1% | Growth Revenue=+4.4%
EPS next Year (2027-12-31): EPS=5.83 | Chg7d=+0.024 | Chg30d=+0.041 | Revisions Net=+6 | Growth EPS=+13.5% | Growth Revenue=+5.4%
[Analyst] Revisions Ratio: -0.50 (2 Up / 6 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.1% (Discount Rate 10.6% - Earnings Yield 4.5%)
[Growth] Growth Spread = -3.0% (Analyst 3.1% - Implied 6.1%)